Twist Bioscience Corporation has released its financial results for the fourth quarter and the full fiscal year 2025, showcasing a strong revenue performance while falling short on earnings per share. The company's results highlight its ongoing growth trajectory in the biotechnology sector, and the publication provides the following information:
Twist Bioscience Reports Q4 Revenue Exceeding Expectations
In the fourth quarter, Twist Bioscience reported a revenue of $99.01 million, exceeding analysts' expectations of $97.37 million. This achievement marks the 11th consecutive quarter of revenue growth for the company, underscoring its robust market position and demand for its products.
Earnings Per Share Falls Short Despite Revenue Growth
Despite the positive revenue figures, the company's earnings per share (EPS) of $0.45 fell short of the anticipated $0.40. This discrepancy reflects ongoing cost pressures that the company is facing, although it also reported a narrowing net loss, indicating some operational improvements.
Optimistic Growth Prospects for Fiscal 2026
Looking forward, Twist Bioscience is optimistic about its growth prospects for fiscal 2026, projecting total revenue to be between $425 million and $435 million. This ambitious forecast suggests the company is positioning itself for significant expansion in the coming year.
In light of Twist Bioscience's recent financial results, nontechnical leaders are exploring innovative strategies to enhance revenue generation. For insights on how to architect a robust go-to-market strategy, read more.
